Journal
ANNALS OF ONCOLOGY
Volume 27, Issue 6, Pages 1161-1164Publisher
OXFORD UNIV PRESS
DOI: 10.1093/annonc/mdw140
Keywords
-
Categories
Ask authors/readers for more resources
This case study of rociletinib, once considered a highly promising drug and now facing significant hurdles for marketing approval, should serve as a cautionary tale for pharmaceutical and biotech companies as well as academic investigators on the dos and don'ts of drug development.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available